Drugs / Diphencyprone

Trials 6 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT05020496 Mar 2022 → Jun 2027 expected skin disorder University of Alabama at Birmingham Active not recruiting No outcome recorded
Phase 13 trials
Phase 1 NCT05481658 Oct 2022 → Dec 2029 expected Nicholas Gulati Recruiting No outcome recorded
Phase 1 NCT01978483 Nov 2013 → Jun 2014 drug allergy, immunodeficiency disease, type IV hypersensitivity disease Innovaderm Research Inc. Completed No outcome recorded
Phase 1 NCT01711684 Oct 2012 → Jun 2015 melanoma, metastatic neoplasm Rockefeller University Completed No outcome recorded
Phase 31 trial
Phase 3 NCT03651752 Apr → Sep 2024 alopecia areata University of Minnesota Terminated No outcome recorded
Phase 41 trial
Phase 4 NCT04775979 Jan → Jul 2021 vitiligo Ain Shams University Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as Diphencyprone ClinicalTrials.gov intervention name — accepted as the source's own label NCT05481658
Known as Diphenylcyclopenone ChEMBL registry synonym — accepted as the source's own label CHEMBL1373467
Known as Diphenylcyclopropenone ClinicalTrials.gov intervention name — accepted as the source's own label NCT01978483
4

NCT05020496

NCT04775979

NCT03651752

NCT01711684

Known as DPCP “Diphenylcyclopropenone (DPCP) Ointment” NCT03651752
2

“Diphenylcyclopropenone (DPCP)” NCT05020496

“Diphencyprone (DPCP)” NCT05481658

Known as NSC-57541 ChEMBL registry synonym — accepted as the source's own label CHEMBL1373467
Modality Small molecule CHEMBL1373467
Route Topical “as a topical immunotherapeutic agent” NCT01711684